Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OliX, Icure IPOs Test Korean Biotech Sentiment Amid Samsung Uncertainties

Executive Summary

OliX Pharmaceuticals and Icure are poised to be first biotech firms to launch IPOs this year amid uncertainties over ongoing accounting issues at Samsung BioLogics and possible tougher accounting reviews on IPO seekers.

You may also be interested in...

Korea To Examine Companies' R&D-Related Accounting For Transparency

In a move to harmonize the pharma and biotech industry's accounting practices with global trends, South Korea’s financial authority will examine companies’ R&D cost-related accounting to check for possible ‘distortions’.

Korea Plays Catch-Up In Digital Therapeutics


Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts